| Date | Title | Description | |
|---|---|---|---|
| 29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 02 Apr 2024 | On business and financial situation | ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia | Download |
| 29 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 22 March and 27 March 2024 | Download |
| 22 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 March and 21 March 2024 | Download |
| 15 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 8 March and 14 March 2024 | Download |
| 12 Mar 2024 | On business and financial situation | ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Apr 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2019 | Download |
| 19 Mar 2019 | R&D: new licenses, patents and registered trademarks | ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | Download |
| 26 Feb 2019 | Informe Anual de Remuneraciones de los Consejeros | ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors | Download |
| 26 Feb 2019 | Informe Anual de Gobierno Corporativo | ROVI releases the 2018 Annual Corporate Governance Report | Download |
| 26 Feb 2019 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |